Metastatic Squamous Non-Small Cell Lung Cancer
Oncology·MeSH: Neoplasm Metastasis
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
3 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| portrazza | ELI LILLY & Co (LLY) |
Phase 3(1)
| Drug | Company |
|---|---|
| pemetrexed | Incyte Corp. (INCY) |
Phase 1(1)
| Drug | Company |
|---|---|
| retifanlimab | Incyte Corp. (INCY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Metastatic Squamous Non-Small Cell Lung Cancer?
BioSniper tracks 3 drugs in development for Metastatic Squamous Non-Small Cell Lung Cancer across 2 companies.
How many clinical trials target Metastatic Squamous Non-Small Cell Lung Cancer?
There are 1 clinical trial targeting Metastatic Squamous Non-Small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of Metastatic Squamous Non-Small Cell Lung Cancer?
The estimated prevalence of Metastatic Squamous Non-Small Cell Lung Cancer is approximately 75.0 per 100,000 population.
Deep-dive into Metastatic Squamous Non-Small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis